Organon Drug Patent Portfolio
Organon owns 12 orange book drugs protected by 53 US patents with Implanon having the least patent protection, holding only 1 patent. And Clarinex with maximum patent protection, holding 14 patents. Given below is the list of Organon's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant | 28 Jul, 2030 | Active |
| US8722037 | X-ray visible drug delivery device | 28 Sep, 2027 | Active |
| US10821277 | Kit for and method of assembling an applicator for inserting an implant | 31 May, 2027 | Active |
| US8888745 | Applicator for inserting an implant | 28 Aug, 2026 | Active |
| US7612058 | Methods for inhibiting sterol absorption | 30 Apr, 2026 | Active |
| US7612058 | Methods for inhibiting sterol absorption | 30 Oct, 2025 | Active |
| US8007830 | Granule formation | 24 Oct, 2022 | Expired |
| US7820199 | Stable extended release oral dosage composition | 28 Sep, 2022 | Expired |
| US7030106 | Sterol absorption inhibitor compositions | 25 Jul, 2022 | Expired |
| US6979463 | Stable extended release oral dosage composition | 28 Mar, 2022 | Expired |
| US7820199 | Stable extended release oral dosage composition | 28 Mar, 2022 | Expired |
| US7030106 | Sterol absorption inhibitor compositions | 25 Jan, 2022 | Expired |
| US7618649 | Extended release oral dosage composition | 19 Jun, 2021 | Expired |
| US7618649 | Extended release oral dosage composition | 19 Dec, 2020 | Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions | 07 Jan, 2020 | Expired |
| US7405223 | Treating allergic and inflammatory conditions | 07 Jan, 2020 | Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions | 07 Jul, 2019 | Expired |
| US7405223 | Treating allergic and inflammatory conditions | 07 Jul, 2019 | Expired |
| US5942519 | Prevention of precipitated acute urinary retention | 23 Oct, 2018 | Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Apr, 2017 | Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Apr, 2017 | Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | 08 Jan, 2017 | Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Oct, 2016 | Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | 25 Oct, 2016 | Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | 08 Jul, 2016 | Expired |
| US5607697 | Taste masking microparticles for oral dosage forms | 07 Dec, 2015 | Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine | 30 Jun, 2015 | Expired |
| US7214683 | Compositions of descarboethoxyloratadine | 30 Jun, 2015 | Expired |
| US7214684 | Methods for the treatment of allergic rhinitis | 30 Jun, 2015 | Expired |
| US5607697 | Taste masking microparticles for oral dosage forms | 07 Jun, 2015 | Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same | 11 May, 2015 | Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine | 30 Dec, 2014 | Expired |
| US7214683 | Compositions of descarboethoxyloratadine | 30 Dec, 2014 | Expired |
| US7214684 | Methods for the treatment of allergic rhinitis | 30 Dec, 2014 | Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same | 11 Nov, 2014 | Expired |
| US5457895 | Method of identifying freeze-dried dosage forms | 01 Apr, 2014 | Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors | 21 Mar, 2014 | Expired |
| US5571817 | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] | 05 Nov, 2013 | Expired |
| US5547957 | Method of treating androgenic alopecia with 5-α reductase inhibitors | 15 Oct, 2013 | Expired |
| US5457895 | Method of identifying freeze-dried dosage forms | 01 Oct, 2013 | Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors | 21 Sep, 2013 | Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose | 02 Jun, 2013 | Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids | 02 Jun, 2013 | Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids | 02 Jun, 2013 | Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids | 02 Jun, 2013 | Expired |
| US5298520 | Triazole containing indole derivatives | 29 Dec, 2012 | Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose | 02 Dec, 2012 | Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids | 02 Dec, 2012 | Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids | 02 Dec, 2012 | Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids | 02 Dec, 2012 | Expired |
| US5886184 | Finasteride processes | 19 Nov, 2012 | Expired |
| US5565473 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | 03 Aug, 2012 | Expired |
| US5602162 | Imidazole, triazole and tetrazole derivatives | 28 Jul, 2012 | Expired |
Latest Legal Activities on Organon's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Organon.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Apr, 2024 | US10821277 |
|
Expire Patent
Critical
| 02 Oct, 2023 | US8007830 |
|
Maintenance Fee Reminder Mailed
Critical
| 19 Apr, 2023 | US8007830 |
|
Expire Patent
Critical
| 28 Nov, 2022 | US7820199 |
|
Maintenance Fee Reminder Mailed
Critical
| 13 Jun, 2022 | US7820199 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Apr, 2022 | US8888745 |
|
Expire Patent
Critical
| 20 Dec, 2021 | US7618649 |
|
Expire Patent
Critical
| 20 Dec, 2021 | US7618649 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Oct, 2021 | US8722037 |
|
Correspondence Address Change
Critical
| 10 Aug, 2021 | US7030106 |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Jul, 2021 | US7618649 |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Jul, 2021 | US7618649 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Apr, 2021 | US7612058 |
| Post Issue Communication - Certificate of Correction | 19 Jan, 2021 | US10821277 |
|
Email Notification
Critical
| 21 Dec, 2020 | US10821277 |
Organon's Drug Patent Litigations
Organon's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 09, 2004, against patent number US7214683. The petitioner , challenged the validity of this patent, with ABERG et al as the respondent. Click below to track the latest information on how companies are challenging Organon's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7405223 | June, 2007 |
Decision
(21 Feb, 2008)
| Melton B. Affrime et al | |
| US7214683 | December, 2004 |
Decision
(24 Mar, 2005)
| ABERG et al | |
Organon's Family Patents
Organon Drug List
Given below is the complete list of Organon's drugs and the patents protecting them.
1. Clarinex
Clarinex is protected by 14 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(3 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(4 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(5 years ago)
| Expired |
| US7405223
(Pediatric)
| Treating allergic and inflammatory conditions |
07 Jan, 2020
(5 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(5 years ago)
| Expired |
| US7405223 | Treating allergic and inflammatory conditions |
07 Jul, 2019
(5 years ago)
| Expired |
| US5607697
(Pediatric)
| Taste masking microparticles for oral dosage forms |
07 Dec, 2015
(9 years ago)
| Expired |
| US7211582
(Pediatric)
| Methods for treating urticaria using descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(9 years ago)
| Expired |
| US5607697 | Taste masking microparticles for oral dosage forms |
07 Jun, 2015
(9 years ago)
| Expired |
| US7211582 | Methods for treating urticaria using descarboethoxyloratadine |
30 Dec, 2014
(10 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(10 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex's drug page
2. Clarinex D 24 Hour
Clarinex D 24 Hour is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7820199
(Pediatric)
| Stable extended release oral dosage composition |
28 Sep, 2022
(2 years ago)
| Expired |
| US6979463 | Stable extended release oral dosage composition |
28 Mar, 2022
(2 years ago)
| Expired |
| US7820199 | Stable extended release oral dosage composition |
28 Mar, 2022
(2 years ago)
| Expired |
| US7618649
(Pediatric)
| Extended release oral dosage composition |
19 Jun, 2021
(3 years ago)
| Expired |
| US7618649 | Extended release oral dosage composition |
19 Dec, 2020
(4 years ago)
| Expired |
| US6100274
(Pediatric)
| 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jan, 2020
(5 years ago)
| Expired |
| US6100274 | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
07 Jul, 2019
(5 years ago)
| Expired |
| US7214683
(Pediatric)
| Compositions of descarboethoxyloratadine |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214684
(Pediatric)
| Methods for the treatment of allergic rhinitis |
30 Jun, 2015
(9 years ago)
| Expired |
| US7214683 | Compositions of descarboethoxyloratadine |
30 Dec, 2014
(10 years ago)
| Expired |
| US7214684 | Methods for the treatment of allergic rhinitis |
30 Dec, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clarinex D 24 Hour's drug page
3. Fosamax
Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5358941
(Pediatric)
| Dry mix formulation for bisphosphonic acids with lactose |
02 Jun, 2013
(11 years ago)
| Expired |
| US5681590
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(11 years ago)
| Expired |
| US6090410
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(11 years ago)
| Expired |
| US6194004
(Pediatric)
| Dry mix formulation for bisphosphonic acids |
02 Jun, 2013
(11 years ago)
| Expired |
| US5358941 | Dry mix formulation for bisphosphonic acids with lactose |
02 Dec, 2012
(12 years ago)
| Expired |
| US5681590 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(12 years ago)
| Expired |
| US6090410 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(12 years ago)
| Expired |
| US6194004 | Dry mix formulation for bisphosphonic acids |
02 Dec, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page
4. Implanon
Implanon is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant |
28 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Implanon's drug page
5. Liptruzet
Liptruzet is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| US5969156
(Pediatric)
| Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jan, 2017
(8 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(8 years ago)
| Expired |
| US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
08 Jul, 2016
(8 years ago)
| Expired |
| US5686104
(Pediatric)
| Stable oral CI-981 formulation and process of preparing same |
11 May, 2015
(9 years ago)
| Expired |
| US5686104 | Stable oral CI-981 formulation and process of preparing same |
11 Nov, 2014
(10 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(10 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Liptruzet's drug page
Explore Our Curated Drug Screens
6. Maxalt-mlt
Maxalt-mlt is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5457895
(Pediatric)
| Method of identifying freeze-dried dosage forms |
01 Apr, 2014
(10 years ago)
| Expired |
| US5457895 | Method of identifying freeze-dried dosage forms |
01 Oct, 2013
(11 years ago)
| Expired |
| US5298520
(Pediatric)
| Triazole containing indole derivatives |
29 Dec, 2012
(12 years ago)
| Expired |
| US5602162
(Pediatric)
| Imidazole, triazole and tetrazole derivatives |
28 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Maxalt-mlt's drug page
7. Nexplanon
Nexplanon is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9757552 | Applicator for inserting an implant |
28 Jul, 2030
(5 years from now)
| Active |
| US8722037 | X-ray visible drug delivery device |
28 Sep, 2027
(2 years from now)
| Active |
| US10821277 | Kit for and method of assembling an applicator for inserting an implant |
31 May, 2027
(2 years from now)
| Active |
| US8888745 | Applicator for inserting an implant |
28 Aug, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexplanon's drug page
8. Propecia
Propecia is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5571817 | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
05 Nov, 2013
(11 years ago)
| Expired |
| US5547957 | Method of treating androgenic alopecia with 5-α reductase inhibitors |
15 Oct, 2013
(11 years ago)
| Expired |
| US5886184 | Finasteride processes |
19 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Propecia's drug page
9. Proscar
Proscar is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5942519 | Prevention of precipitated acute urinary retention |
23 Oct, 2018
(6 years ago)
| Expired |
| US5886184 | Finasteride processes |
19 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Proscar's drug page
10. Singulair
Singulair is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8007830 | Granule formation |
24 Oct, 2022
(2 years ago)
| Expired |
| US5565473
(Pediatric)
| Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
03 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Singulair's drug page
11. Vytorin
Vytorin is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE37721
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(8 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(8 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(10 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vytorin's drug page
12. Zetia
Zetia is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7612058
(Pediatric)
| Methods for inhibiting sterol absorption |
30 Apr, 2026
(1 year, 3 months from now)
| Active |
| US7612058 | Methods for inhibiting sterol absorption |
30 Oct, 2025
(9 months from now)
| Active |
| US7030106
(Pediatric)
| Sterol absorption inhibitor compositions |
25 Jul, 2022
(2 years ago)
| Expired |
| US7030106 | Sterol absorption inhibitor compositions |
25 Jan, 2022
(2 years ago)
| Expired |
| USRE37721
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE42461
(Pediatric)
| Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Apr, 2017
(7 years ago)
| Expired |
| USRE37721 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(8 years ago)
| Expired |
| USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
25 Oct, 2016
(8 years ago)
| Expired |
| US5846966
(Pediatric)
| Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Mar, 2014
(10 years ago)
| Expired |
| US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
21 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zetia's drug page